secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-05-14T20:16:28+00:00
Accession:  0001437749-26-017063
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma Q1 product sales $24.3M (+73% YoY); raises FY2026 guidance to >$120M
--------------------------------------------------------------------------------

- Q1 product sales $24.3M (+73% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.14, Adj. EBITDA $5.7M (24% margin)
- Raises full-year 2026 revenue guidance to >$120M from prior $110M; expects ≥30% Adj. EBITDA margin
- Launched DESMODA (FDA-approved oral desmopressin solution); acquired and relaunched HEMANGEOL on May 1
- Initiated ET-700 clinical study (extended-release zinc acetate for Wilson disease); FDA cleared INCRELEX label harmonization study
- Net income of $1.6M vs net loss of $1.6M in Q1 2025; cash $19.7M after $14M HEMANGEOL acquisition

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/0001437749-26-017063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/eton20260322_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer